Formulation Development and Dissolution Rate Enhancement of Efavirenz by Solid Dispersion Systems

por Koh, P. T., Chuah, J. N., Talekar, Meghna, Gorajana, A., Garg, S.
Publicado 2013

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

por Haslett, K., Koh, P., Hudson, A., Ryder, W.D., Falk, S., Mullan, D., Taylor, B., Califano, R., Blackhall, F., Faivre-Finn, C.
Publicado 2021

An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancer...

por Tang, H M, Kuay, K T, Koh, P F, Asad, M, Tan, T Z, Chung, V Y, Lee, S C, Thiery, J P, Huang, RY-J
Publicado 2016

PO-1198 Changes in radical radiotherapy for lung cancer patients in the UK during the COVID-19 pandemic.

por croxford, W., Banfill, K., Fornacon-Wood, I., Britten, A., Carson, C., Hatton, M., Thippu Jayaprakash, K., Jegannathen, A., Keng Koh, P., Panakis, N., Peedell, C., Pope, A., Powell, C., Stilwell, C., Thomas, B., Wood, V., Yun Zhou, S., Price, G., Faivre-Finn, C.
Publicado 2021

Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK

por Banfill, K., Croxford, W., Fornacon-Wood, I., Wicks, K., Ahmad, S., Britten, A., Carson, C., Dorey, N., Hatton, M., Hiley, C., Thippu Jayaprakash, K., Jegannathen, A., Koh, P., Panakis, N., Peedell, C., Pope, A., Powell, C., Stilwell, C., Thomas, B., Toy, E., Wood, V., Yahya, S., Zhou, S.Y., Price, G., Faivre-Finn, C.
Publicado 2022